Stockreport

IO Biotech's melanoma treatment trial to continue after IDMC review [Yahoo! Finance]

IO Biotech, Inc.  (IOBT) 
PDF of the investigational therapeutic vaccine IO102-IO103, in combination with KEYTRUDA (pembrolizumab) for advanced melanoma. This development follows a per-protocol int [Read more]